We are live on ! Find out more
CA

CHI Advisors Portfolio holdings

AUM $252M
1-Year Est. Return 56.99%
This Fund
S&P 500
This Quarter Est. Return
+29.17%
1 Year Est. Return
+56.99%
3 Year Est. Return
+88.23%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$355M
AUM Growth
+$73.9M
Cap. Flow
+$27.7M
Cap. Flow %
7.79%
Top 10 Hldgs %
95.82%
Holding
25
New
3
Increased
7
Reduced
9
Closed
2
Avg Time Held Equity + Options
2.8 quarters
Top 10 Avg Time Held Equity + Options
2.2 quarters
Top 20 Avg Time Held Equity + Options
2.9 quarters
Avg Time Held Equity only
3.2 quarters
Top 10 Avg Time Held Equity only
2.2 quarters
Top 20 Avg Time Held Equity only
2.9 quarters

Top Buys

Rank Stock Value
1
ONCR
Oncorus, Inc.
ONCR
+$38.9M
2
OVID icon
Ovid Therapeutics
OVID
+$975K
3
FRLN
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
+$615K
4
AKUS
Akouos Inc
AKUS
+$477K
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$335K

Top Sells

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$8.55M
2
DTIL icon
Precision BioSciences
DTIL
+$1.33M
3
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$954K
4
KZR icon
Kezar Life Sciences
KZR
+$621K
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$534K

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
2 Miscellaneous 0.02%
3 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
RPTX icon
1
DELISTED
Repare Therapeutics
RPTX
$86.9M 24.47%
2,532,150
+1,656
+0.1% +$49.5K
2020 Q2
2 quarters
ONCR
2
DELISTED
Oncorus, Inc.
ONCR
$54.3M 15.3%
+1,679,906
New +$38.9M
2020 Q4
0 quarters
PLRX icon
3
Pliant Therapeutics
PLRX
$61.3M
$53.5M 15.07%
2,354,799
+2,508
+0.1% +$62.9K
2020 Q2
2 quarters
LRMR icon
4
Larimar Therapeutics
LRMR
$264M
$32.4M 9.14%
1,515,148
– –
2020 Q2
2 quarters
KROS icon
5
Keros Therapeutics
KROS
$230M
$30.6M 8.62%
433,852
-135,606
-24% -$8.55M
2020 Q2
2 quarters
FRLN
6
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
$24.9M 7%
90,738
+2,447
+3% +$615K
2020 Q3
1 quarter
INZY icon
7
DELISTED
Inozyme Pharma
INZY
$20.5M 5.79%
995,396
-13,721
-1% -$327K
2020 Q3
1 quarter
AKUS
8
DELISTED
Akouos Inc
AKUS
$17.3M 4.86%
870,897
+24,500
+3% +$477K
2020 Q2
2 quarters
ORTX
9
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$12.7M 3.57%
293,119
– –
2019 Q3
5 quarters
DTIL icon
10
Precision BioSciences
DTIL
$181M
$7.11M 2%
28,412
-5,416
-16% -$1.33M
2019 Q3
5 quarters
AMWL icon
11
American Well
AMWL
$212M
$6.29M 1.77%
12,418
– –
2020 Q3
1 quarter
OVID icon
12
Ovid Therapeutics
OVID
$469M
$1.91M 0.54%
827,260
+209,168
+34% +$975K
2019 Q3
5 quarters
CRVS icon
13
Corvus Pharmaceuticals
CRVS
$845M
$1.75M 0.49%
490,877
-92,355
-16% -$372K
2019 Q3
5 quarters
GTHX icon
14
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$1.11M 0.31%
62,000
-22,000
-26% -$329K
2020 Q2
2 quarters
GBT
15
DELISTED
Global Blood Therapeutics, Inc.
GBT
$987K 0.28%
22,800
+6,800
+43% +$335K
2019 Q3
5 quarters
KZR icon
16
DELISTED
Kezar Life Sciences
KZR
$705K 0.2%
13,500
-11,164
-45% -$621K
2019 Q3
5 quarters
ADVM icon
17
DELISTED
Adverum Biotechnologies
ADVM
$642K 0.18%
5,921
-1,079
-15% -$133K
2020 Q1
3 quarters
BPMC icon
18
DELISTED
Blueprint Medicines
BPMC
$617K 0.17%
5,500
-1,000
-15% -$105K
2019 Q3
5 quarters
RARE icon
19
Ultragenyx Pharmaceutical
RARE
$1.51B
$415K 0.12%
3,000
-4,500
-60% -$534K
2019 Q3
5 quarters
BLUE icon
20
DELISTED
bluebird bio
BLUE
$346K 0.1%
618
– –
2019 Q3
5 quarters
XBI icon
21
PUT
State Street SPDR S&P Biotech ETF
XBI
$10B
$54K 0.02%
+10,000
New +$1.28M
2020 Q4
0 quarters
DTIL icon
22
CALL
Precision BioSciences
DTIL
$181M
$8K ﹤0.01%
+333
New +$81.6K
2020 Q4
0 quarters
GBT
23
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
$8K ﹤0.01%
20,000
+10,000
+100% +$493K
2020 Q3
1 quarter
MYOK
24
DELISTED
MyoKardia, Inc. Common Stock
MYOK
– –
-7,000
Closed -$954K –
LVGO
25
DELISTED
Livongo Health, Inc. Common Stock
LVGO
– –
-3,640
Closed -$510K –

Similar funds

SC
Samjo Capital New York $254M AUM 36.81% 1-Year Est. Return
T
TRUADVICE Sarasota, Florida $255M AUM 14.45% 1-Year Est. Return
W
WealthOne Albany, New York $248M AUM 17.79% 1-Year Est. Return
RBGI
Ribbit Bullfrog GP II Palo Alto, California $258M AUM 33.43% 1-Year Est. Return
TOGEPT
Trustees of General Electric Pension Trust Norwalk, Connecticut $245M AUM 128.88% 1-Year Est. Return
IAM
Innovis Asset Management Chicago, Illinois $260M AUM 28.13% 1-Year Est. Return
RCGI
Ribbit Capital GP II Palo Alto, California $260M AUM 2.87% 1-Year Est. Return
AEPLI
AH Equity Partners LSV III Menlo Park, California $262M AUM 59.24% 1-Year Est. Return

CHI Advisors's Q4 2020 Portfolio in Review

As of Q4 2020, CHI Advisors held 25 positions worth $355M, up 26% from $281M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

CHI Advisors deployed $27.7M of net new capital in Q4 2020, opening 3 new positions and adding to 7 existing holdings. Its largest new stake was Oncorus, Inc.: 1,679,906 shares worth $54.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous and Communication Services.

On the sell side, the largest reduction was Keros Therapeutics, an estimated $8.55M trimmed.

  • CHI Advisors's largest Q4 2020 buy was Oncorus, Inc.: 1,679,906 shares worth $54.3M.
  • CHI Advisors added most to Ovid Therapeutics in Q4 2020, an estimated $975K increase.
  • CHI Advisors's biggest Q4 2020 reduction was Keros Therapeutics, cutting an estimated $8.55M.
  • CHI Advisors fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $954K.
  • CHI Advisors's ten largest holdings make up 96% of its $355M portfolio in Q4 2020.
  • CHI Advisors opened 3 new positions and closed 2 in Q4 2020.
  • CHI Advisors's portfolio value rose 26% quarter-over-quarter to $355M.

Based on CHI Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.